# GLP-1 receptor agonists: Evolution

Source page: https://www.materialinsights.org/technologies/glp1_agonists/tech-evolution/

#### Timeline

The milestones from first idea to today

| Year | Milestone |
|---|---|
| 1987 | GLP-1 (7 to 37) is shown to trigger insulin release from the pancreas ^[1] |
| 1992 | John Eng finds exendin-4 in Gila monster venom ^[2] |
| 2005 | Exenatide (Byetta) is approved by the US Food and Drug Administration ^[2] |
| 2010 | Liraglutide, a modified human GLP-1 lasting a day, is approved in the United States for diabetes ^[1] |
| 2014 | Liraglutide is approved for obesity in the United States ^[1] |
| 2017 | Semaglutide (Ozempic) is approved for diabetes; it is approved for obesity (Wegovy) in 2021 ^[1] |
| 2023 | Tirzepatide, which also acts on a second gut hormone receptor (GIP), is approved for weight loss in the United States ^[1] |
| 2025 | WHO adds GLP-1 medicines to its Essential Medicines List and issues a global guideline on their use for obesity ^[3] |

as of 2026-11-11

#### Lineage

The technologies it came from and the ones that came from it
 Works with

- [Inl Insulin therapy](https://www.materialinsights.org/technologies/insulin_therapy/) Both treat diabetes; GLP-1 drugs make the body release its own insulin when blood sugar is high ^[1].
 Builds on

- [rDNA Recombinant DNA (genetic engineering)](https://www.materialinsights.org/technologies/recombinant_dna/) GLP-1 was found by cloning and reading the glucagon gene in the 1980s ^[1].
- [Asa Synthetic drugs (medicinal chemistry)](https://www.materialinsights.org/technologies/synthetic_drugs/) The drugs are made-to-order molecules designed to fit a known receptor, as in modern drug design.

as of 2026-11-11

#### Sources

1. [GLP-1-based therapy for obesity](https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/) Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
2. [Dr. John Eng to Receive Golden Goose Award](https://www.sciencecoalition.org/2013/07/30/dr-john-eng-to-receive-golden-goose-award/) The Science Coalition, 2013
3. [WHO issues global guideline on the use of GLP-1 medicines in treating obesity](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity) World Health Organization, 2025

## Other sections

- [Summary](https://www.materialinsights.org/technologies/glp1_agonists/index.md)
- [Overview](https://www.materialinsights.org/technologies/glp1_agonists/tech-overview/index.md)
- [Science](https://www.materialinsights.org/technologies/glp1_agonists/tech-science/index.md)
- [Materials](https://www.materialinsights.org/technologies/glp1_agonists/tech-materials/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/glp1_agonists/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/glp1_agonists/tech-industries/index.md)
